Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study

BACKGROUND AND OBJECTIVE: There is no licensed treatment for refractory chronic cough; off-label therapies have limited efficacy and can produce adverse effects. Excessive adenosine triphosphate signaling via P2X3 receptors is implicated in refractory chronic cough, and selective P2X3 receptor antag...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedrich, Christian, Francke, Klaus, Gashaw, Isabella, Scheerans, Christian, Klein, Stefan, Fels, Lueder, Smith, Jaclyn A., Hummel, Thomas, Morice, Alyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349145/
https://www.ncbi.nlm.nih.gov/pubmed/35624408
http://dx.doi.org/10.1007/s40262-022-01126-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349145/
https://www.ncbi.nlm.nih.gov/pubmed/35624408
http://dx.doi.org/10.1007/s40262-022-01126-1

Ejemplares similares